In this closing segment on advanced renal cell carcinoma, Dr. Wulff invites final reflections on anticipated changes in treatment guidelines over the coming year.
Daniel Geynisman, MD
Daniel Geynisman, MD, is a medical oncologist specializing in genitourinary cancers at Fox Chase Cancer Center.
Articles by Daniel Geynisman, MD
In this segment on advanced renal cell carcinoma, Dr. Geynisman focuses on key principles for applying NCCN guideline recommendations in real-world community practice.
In this segment on advanced renal cell carcinoma, Dr. McGregor highlights the challenges of managing comorbidities in community practice and how these factors influence treatment selection. Dr. Wulff and Dr. Geynisman discuss practical strategies for adapting guideline-based therapies in patients with cardiovascular disease, pulmonary conditions, and baseline anemia.
In this segment on advanced renal cell carcinoma, Dr. Geynisman discusses how clinicians decide between single-agent TKIs and combination approaches in later-line treatment settings.
In this segment on advanced renal cell carcinoma, Dr. Wulff explores how the potential incorporation of belzutifan-based regimens into NCCN recommendations could influence future treatment sequencing.
In this segment on advanced renal cell carcinoma, Dr. McGregor introduces emerging data from the LITESPARK-011 study evaluating belzutifan in combination with lenvatinib compared with cabozantinib in previously treated patients.
In this segment on advanced renal cell carcinoma, Dr. Geynisman focuses on the clinical scenarios in which cabozantinib is selected following progression on first-line therapy.
In this segment on advanced renal cell carcinoma, Dr. Wulff transitions the discussion to treatment sequencing after progression on first-line IO-based therapy.
In this segment on advanced renal cell carcinoma, Dr. McGregor focuses on how clinicians move beyond guideline recommendations when multiple appropriate treatment options are available.
In this segment on advanced renal cell carcinoma, Dr. Geynisman raises the increasingly relevant question of how prior adjuvant pembrolizumab or earlier immunotherapy exposure influences treatment selection in the metastatic setting.
In this segment on advanced renal cell carcinoma, Dr. Wulff focuses on the role of cabozantinib across different treatment settings and how clinicians decide between monotherapy and combination approaches in practice.
In this segment on advanced renal cell carcinoma, Dr. McGregor explores the role of VEGFR TKI monotherapy in patients with favorable risk disease, where NCCN guidelines include both IO-TKI combinations and, in select cases, TKI alone.
In this segment focused on advanced renal cell carcinoma, Dr. Geynisman shifts the discussion to patients with intermediate and poor risk disease based on IMDC criteria and how this influences first-line treatment selection. Dr. McGregor and Dr. Wulff discuss how NCCN recommendations support both IO-IO and IO-TKI combinations in this population, while emphasizing that clinical context often guides the final decision.
In this introductory segment on advanced renal cell carcinoma, Dr. Wulff frames the challenge of selecting among multiple NCCN category 1 first-line regimens, including IO-IO and IO-TKI combinations. Dr. McGregor and Dr. Geynisman discuss how they approach treatment selection in clinical practice when several evidence-based options exist.
